Nucryst receives European approval for Acticoat Moisture Control

By Lisa Kerner

Erie, Pa., Feb. 6 - Nucryst Pharmaceuticals said its Acticoat Moisture Control with Silcryst nanocrystals received European Design Examination Certificate regulatory approval.

The product, cleared by the Food and Drug Administration and Health Canada in 2005, will be available in Europe beginning March 1, according to a company news release.

Acticoat Moisture Control is a foam dressing that provides antimicrobial activity for up to seven days for wounds with light to moderate exudate (oozing).

The product, developed in collaboration with Smith & Nephew, will be sold by Smith & Nephew as part of its Acticoat product line.

"We are pleased that doctors and patients in Europe can now get the benefit of the full line of Acticoat products," Scott H. Gillis, Nucryst president and chief executive officer, said in the release.

"As part of our long-term growth strategy, we will continue to look for further opportunities to develop innovative medical products to fight infection and inflammation using our proprietary nanocrystalline silver technology."

Acticoat products are used for a wide variety of wound types in hospitals, clinics, burn centers, doctors' offices, home health care agencies and nursing homes.

Nucryst develops, manufactures and commercializes medical products that fight infection and inflammation based on its nanocrystalline silver technology. The company is based in Wakefield, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.